Diabetes on the Net is intended for healthcare professionals

back to main site

Back to home page

How to assess frailty in your practice and what treatment options should you consider

This video was originally broadcasted on 1 July 2020

This promotional webinar series and respective materials have been developed, organised and funded by Novo Nordisk.
For healthcare professionals only. 

Promotional information on insulin degludec (Tresiba®) will be discussed in this webinar. Click here to view prescribing information and adverse event reporting information for insulin degludec (Tresiba®). Insulin degludec (Tresiba®) is indicated for the treatment of diabetes mellitus in adults, adolescents and children from the age of 1 year.

Related webinar

Date of prep: December 2020 – Job code: UK20TSM00258

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.Adverse events should also be reported to Novo Nordisk Limited (Telephone Novo Nordisk Customer Care Centre 0845 6005055). Calls may be monitored for training purposes.

© Copyright omniamed Communications. All Rights Reserved